"Dr. Anton is a Professor of Medicine within the Division of Digestive Diseases and a member of the UCLA AIDS Institute. He is Director of the UCLA CFAR Mucosal Immunology Research Laboratory (MICL), Director of the UCLA Center for HIV Prevention Research (CPR), and past Director of the Inflammatory Bowel Disease (IBD) Center at UCLA. He also serves as the Director of Mentoring for the Division and co-Director of the NIDDK Gastroenterology Training Grant. Dr. Anton graduated magna cum laude from Harvard University in 1977 and received his MD from Case Western Reserve University in 1983. He did fellowship work at the Cholera Hospital, ICDDR, in Bangladesh in 1983 and a year fellowship in pathology in 1981 in Cleveland’s Institute of Pathology. He performed his internship and residency in internal medicine at Bringham and Women’s Hospital in Boston Massachusetts. Dr. Anton began in his work at UCLA in 1986 with a Gastroenterology Fellowship and has been on faculty since 1989. Dr. Anton’s research focuses on the degree of mucosal inflammation and altered co-receptor expression associated with HIV infection and associated therapeutic interventions, the potential use of the mucosa as a route of HIV immunization with various HIV vaccine candidates as well as microbicides for HIV mucosal prevention, investigating the interaction of HSV and HIV in mucosal pathogenesis and efforts to clarify the role of compartments in HIV pathogenesis. He has been PI on over 30 clinical trials including two Phase 1 HIV vaccine trials and two Phase 1 anti-HIV topical microbicide trials. He recently completed research as PI of the NIH IPCP U19 award “Microbicide Development Program” (MDP), with national/international sub-study sites, focusing on a developmental pipeline for rectal microbicides. He currently heads the Clinical Trials Project within the second IPCP U19 Combination HIV Antiretroviral Rectal Microbicide (CHARM)(Dr Ian McGowan, PI, University of Pittsburgh) which will have six exploratory pre-Phase I microbicide trials during the 5-year award."

Mucosal inflammation and altered co-receptor expression associated with HIV infection and associated therapeutic interventions, the potential use of the mucosa as a route of HIV immunization with various HIV vaccine candidates as well as microbicides for HIV mucosal prevention, investigating the interaction of HSV and HIV in mucosal pathogenesis and efforts to clarify the role of compartments in HIV pathogenesis.